A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis

Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms SPRINT-MS
  • Sponsors MediciNova
  • Most Recent Events

    • 10 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 28 Apr 2017 Results (n=261) presented at the 69th Annual Meeting of the American Academy of Neurology
    • 19 Dec 2016 According to a MediciNova media release, the external Data and Safety Monitoring Board (DSMB) for this trial has reviewed the results of the interim efficacy analysis and made the recommendation that the trial should continue as planned.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top